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Abstract. Before 1989, dengue epidemiology in Sri Lanka was characterized by frequent transmission of all four
dengue serotypes but a low incidence of dengue hemorrhagic fever (DHF). After 1989, cases of DHF dramatically
increased. Here we present the results of epidemiologic studies conducted in Colombo, Sri Lanka before and after
epidemic emergence of DHF in 1989. We compared the proportion of dengue cases among people with fever attending
clinics from 1980 to 1984 and in 1997 and 1998 to determine if an increase in dengue transmission was associated with
more DHF cases being reported. We also compared the relative distribution of dengue virus serotypes circulating in
Colombo before and after the emergence of DHF. We detected no significant differences in dengue as a proportion of
fever cases or in serotype distribution between the pre and post-DHF periods. We conclude that an increase in virus
transmission or a change in circulating serotypes does not explain the epidemic emergence of DHF in Sri Lanka.
INTRODUCTION
Dengue viruses are mosquito-borne flaviviruses that have
plagued people for centuries.1 Starting in the middle of the
20th century, large-scale urbanization and increasing human
populations in tropical parts of the world created conditions
especially favorable for dengue transmission. These changes
led to the current global dengue pandemic, which is charac-
terized by a dramatic increase in dengue infections and an
expanding geographic distribution of both the viruses and the
mosquito vector, Aedes aegypti.1
Most people infected with dengue viruses are asymptom-
atic or develop dengue fever (DF). The signs and symptoms
of DF include high fever, myalgia, headache, vomiting, and
loss of appetite.2,3 Although dengue fever is a serious, debili-
tating condition, it is usually not fatal. A minority of people
infected with dengue viruses develop dengue hemorrhagic fe-
ver and dengue shock syndrome (DHF/DSS). The acute
phase of DHF/DSS begins similar to that in DF but patients
then abruptly develop a severe vascular permeability syn-
drome that may lead to shock and death.2,3
The distribution of DHF/DSS in Asia has been particularly
enigmatic. Before 1989, DHF was common in Southeast Asia
but rare in the Indian subcontinent despite hyperendemic
transmission of dengue viruses in both regions.1,4 In 1989, this
pattern of severe disease changed and regular epidemics of
DHF have been reported from several countries in the Indian
subcontinent.1,4 Here we report the results of epidemiologic
studies that were done to understand factors responsible for
the recent emergence of epidemic DHF in Sri Lanka.
There are four distinct serotypes of dengue virus, desig-
nated DEN-1, DEN-2, DEN-3, and DEN-4. Infection with
one serotype confers immunity to that serotype but not to
heterologous serotypes.5 Both retrospective and prospective
studies have demonstrated that a person experiencing a sec-
ondary dengue infection is at a greater risk of developing
DHF/DSS than a person experiencing a primary infection.6,7
To explain the increased risk of severe disease with secondary
infection, Halstead has proposed that cross-reactive antibody
from the primary infection enhances a secondary infection by
binding to virus and increasing uptake into FC receptor-
bearing target cells of the monocytic/ macrophage lineage.8,9
More recently, this antibody-dependent enhancement (ADE)
model has been further expanded to include roles for cellular
immunity and host cytokines and chemical mediators in the
pathogenesis of DHF.10
However, ADE alone does not sufficiently explain severe
disease because DHF is observed in primary cases, and not all
secondary cases develop DHF.11–17 Epidemiologic studies
point to particular dengue virus strains being more virulent
than others.16–19 Historically the dengue genotypes endemic
to Central and South America have caused mild disease,
while the introduction of Asian genotypes to the region has
led to DHF epidemics.20–23 Similarly, outbreaks of DHF in
some Pacific islands have been traced to the introduction of
Southeast Asian dengue strains.24 The current consensus in
the field is that certain virulent genotypes cause severe dis-
ease, most often, in the context of a secondary infection.7,19
To further understand the interplay between viral strains
and secondary infections in severe disease, we have studied
the epidemiology of dengue in Colombo, Sri Lanka where
DHF has emerged as a serious public health threat relatively
recently. The Indian subcontinent, where all four virus sero-
types are present, did not have regular epidemics of DHF/
DSS before 1989. Small outbreaks occurred in India in 1963
and in Sri Lanka in 1965−1966.4 In the Sri Lankan 1965−1966
epidemic, 26 cases of DHF/DSS were documented with six
deaths (Medical Research Institute [MRI], Colombo, Sri
Lanka, unpublished data). DEN-1 and DEN-2 viruses were
isolated from the outbreak. Thereafter, DHF cases were only
reported sporadically (< 10 cases/year) from Sri Lanka until
1989 when the incidence of DHF abruptly increased, with 206
hemorrhagic cases being reported.4,25 Since 1989, DHF rates
have averaged more than 800 cases per year (Figure 1).26 A
similar increase in the number of DHF cases was reported
from several major Indian cities in the 1990s.4,27 The 1990s
saw a long-term shift in the pattern of dengue disease in the
Indian subcontinent, and the region now has regular epidem-
ics of DHF/DSS.
To understand the sudden and long-term increase in DHF
cases in Sri Lanka, we have compared the epidemiology of
dengue infections before (1980−1984) and after (1997−1998)
epidemic DHF emergence in Colombo, Sri Lanka. Specifi-
cally, we present data on three aspects of dengue epidemiol-
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ogy: 1) the proportion of dengue cases among people with
fever attending primary care clinics, 2) the ratio of primary
and secondary dengue infections among dengue cases in both
clinics and hospital wards, and 3) the relative abundance of
dengue serotypes isolated from DF cases. Our data demon-
strate that the intensity of dengue transmission and the rela-
tive abundance of each serotype have remained stable after
the emergence of DHF. The reason for the emergence of
DHF in Sri Lanka is more complex than a simple increase in
the intensity of virus transmission or the displacement of one
serotype by a different serotype.
MATERIALS AND METHODS
Study site. Sri Lanka is an island with an area of 65,000 km2
(436 km long and 225 km wide) that is located 33 km south of
India. The current study was conducted in the coastal city of
Colombo, which is located on the southwestern side of the
island. Colombo is the largest city in the country with a popu-
lation of approximately 600,000 in 1980−1985 and nearly one
million in 1998. The average annual rainfall in Colombo is
2,240 mm, with the bulk of the rain falling from May to Au-
gust (southwest monsoon) and less from November to Janu-
ary (northeast monsoon). The average temperature ranges
between 25 and 30°C.
Prospective study among school children in Colombo
(1980−1985). Nine schools located within walking distance
from the municipal clinics were selected to enroll students for
the prospective school cohort study. Blood samples were
taken from primary school children (5−7 years old). Each
cohort of 5−7-year-old children was bled in October and six
months later in April of the following year. Five cohorts were
tested from 1980 to 1985. Blood was obtained by finger stick
and collected onto two fully saturated filter paper discs (1.0
cm diameter) and into five microcapillary tubes. The filter
paper discs were air-dried, stored in a freezer (−10°C to 20°C),
and tested as pairs (six months apart) by the hemagglutina-
tion inhibition (HI) test to determine seroconversion rates.
The ethical clearance committee of the MRI in Colombo, Sri
Lanka approved the protocol for collecting blood for the
school cohort study.
Surveillance of patients with fever attending clinics
(1980−1984). For the fever surveillance study, five study areas
were chosen to obtain proper geographic, ethnic, and socio-
economic representation of the city population. Two of the
areas were located in the northern part of the city, two in the
central part, and one in the southern part. These study areas
covered 24 of the 47 municipal wards in Colombo. In each of
the five study areas, a municipal clinic and a private practi-
tioner clinic were selected for case enrollment by a team con-
sisting of a physician, nurse and public health inspector. Each
day of the week (Monday–Friday) was devoted to enrolling
patients at the clinics in one study area so that over the five-
day week patients were enrolled from all five study areas. In
addition to the municipal clinics, the outpatient clinic at the
Lady Ridgeway Children’s Hospital (LRH) was also visited
weekly to enroll patients. Only patients with a fever of un-
known origin (no respiratory, diarrheal, or other obvious
cause for the fever) were enrolled in the study. A clinical
history was obtained and a physical examination was per-
formed on each patient enrolled in the study. A venous blood
sample was taken from each patient and the samples were
taken to the MRI in a vacuum flask on wet ice at the end of
the morning’s work. A convalescent blood sample was col-
lected from most patients two weeks later by appointment at
the clinic or by going to the patient’s home. Records for which
patient data were incomplete were excluded from all analy-
ses. The ethical clearance committee of the MRI in Colombo,
Sri Lanka approved the protocol for dengue surveillance at
clinics. These two early studies were designed and conducted
by two of the co-investigators (UTV and DJG).
Surveillance of patients with fever attending the LRH out-
patient clinic (1997−1998). Fever cases were enrolled between
July 4, 1997 to August 8, 1997 and again from December 17,
FIGURE 1. Cases of dengue hemorrhagic fever (DHF) in Sri Lanka, 1980−1998. The data are based on cases reported to the Epidemiology Unit
of the Ministry of Health and cases tested at the Medical Research Institute (MRI) in Colombo. The case definition for DHF consists of at least
fever, hemorrhagic symptoms, and a platelet count < 100,000/mm3. Serologic confirmation was based on the hemagglutination inhibition test.
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1997 to January 26, 1998. This study is collectively referred to
as the 1997−1998 clinic study. The protocol for enrolling pa-
tients was similar to the 1980−1984 clinic study except for the
following changes: patients were only enrolled at the LRH
outpatient clinic, and the study was restricted to children be-
tween the ages of one and 12. Researchers visited the clinic
daily from 9:00 AM to noon to collect sera from patients pre-
senting with a dengue-like illness for four or fewer days. To
obtain convalescent samples, the patients were asked to re-
turn at least six days after the onset of fever. The time interval
between acute and convalescent samples was reduced in the
post DHF study because an IgM enzyme-linked immunosor-
bent assay (ELISA) and a reverse transcriptase−polymerase
chain reaction (RT-PCR) assay were used in addition to the
HI test in diagnosing dengue infections. Records for which
patient data were incomplete were excluded from statistical
analyses. The ethical clearance committee of the MRI in Co-
lombo, Sri Lanka approved the protocol for dengue surveil-
lance at the LRH clinic.
Surveillance of suspected DHF patients admitted to the
LRH wards (1997−1998). Data for this study were collected
between August 5, 1997 and August 14, 1997 and from July
13, 1998, to August 20, 1998. Children suspected of having
DHF were admitted to six wards at the LRH. Suspected DHF
cases are referred from the LRH outpatient clinic as well as
other government and private clinics in Sri Lanka. The MRI
staff visited all the medical wards at the LRH every day to
collect blood from suspected DHF cases. An acute sample
was collected as soon as possible after admission and a second
sample was collected on the day of discharge from hospital.
The patients’ charts were read and the attending physicians
were consulted to record the clinical and physical findings as
well as the clinical laboratory test results. Records for which
patient data were incomplete were excluded from all analy-
ses.
Hemagglutination inhibition test. Only paired samples
were analyzed from the 1980−1984 study. Samples were
tested by the HI test using the method of Clarke and Casals
modified for microtiter plates.28 All antigens were prepared
from mouse brain infected with prototype viruses and ex-
tracted with sucrose-acetone. Nonspecific inhibitors in sera
were removed by extraction with kaolin, and agglutinins were
removed by extraction with goose red blood cells. The anti-
gens used in the HI test were obtained from two dengue
serotypes (serotype 1 and 2, or 3 and 4), Japanese Encephalitis
virus, and Sindbis virus. The samples were tested at two-fold
dilutions up to a dilution of 1:2,560. The HI test was per-
formed as described above for the 1997−1998 samples except
that Japanese encephalitis and Sindbis antigen were not used.
Isolation of virus. All samples from 1980−1985 and
1989−1996 were sent to the Dengue Branch of the Centers for
Disease Control and Prevention (CDC) in San Juan, Puerto
Rico for virus isolation by the mosquito inoculation technique
using adult Aedes aegypti and/or Toxorhynchites amboinen-
sis29 or infection of C6/36 cells grown in Eagle’s minimum
essential medium supplemented with 5% fetal calf serum.30
Serum samples, stored at −70°C, were thawed and inoculated
intrathoracically into mosquitoes undiluted and at a dilution
of 1:5 in phosphate-buffered saline (PBS) containing 20%
heat-inactivated calf serum. Inoculated mosquitoes were held
at 30°C for 14 days, killed by freezing, and stored at −70°C
until tested for virus. Mosquito brain squashes were examined
by the direct fluorescent antibody (DFA) test for the pres-
ence or absence of viral antigen using a conjugate prepared
from high-titered human serum.30 The C6/36 cells were in-
fected with 50 L of undiluted acute serum (< 5 days) and
incubated for seven days at 32°C. Cells were fixed to slides
with cold buffered acetone and infecting virus was identified
by DFA followed by IFA using serotype-specific monoclonal
antibodies30 and/or an RT- PCR.31
RT-PCR. Virus was detected and identified by RT-PCR
using the method developed by Lanciotti and others31 Briefly,
RNA was extracted by the guanidine isothiocyanate method
or using a commercially available RNA isolation kit (viral
isolation kit; Qiagen, Valencia, CA). Target viral RNA was
converted to cDNA by reverse transcriptase Rous-associated
virus-2 and consensus downstream primer D2. The cDNA
was amplified by a nested PCR using Taq polymerase and
consensus primers D1 and D2 in the first round of amplifica-
tion and replacing primer D1 with serotype-specific primers
TS1-TS4 in the second round of amplification. Second-round
PCR products were visualized and analyzed by electrophore-
sis on agarose gels stained with ethidium bromide.
IgM ELISA. Samples collected in the 1997−1998 studies
were tested by IgM capture ELISA.32 For the IgM ELISA,
96-well plates were coated with goat anti-human IgM anti-
body, to which serum samples diluted 1:40 were added, fol-
lowed by a dengue antigen mixture (D1, 2, 3, 4) and horse-
radish peroxidase (HRP)−conjugated anti-flavivirus mono-
clonal antibody. After addition of HRP substrate, sera were
scored as positive for infection if the optical density at 405 nm
(OD405) was  0.2.
IgG ELISA. Samples collected in the 1997−1998 ward
study were tested by IgG ELISA using a modification of the
method described by Chungue and others.33 Briefly, hyper-
immune ascites fluid (anti D1-D4) was added to each well of
96-well plates and incubated overnight at 4°C. Plates were
washed three times with PBS, blocked with standard diluent,
and incubated for one hour at 37°C, followed by the addition
of a D1-D4 antigen mixture and incubation at 37°C for an
additional hour. After the plates were washed three times in
PBS, a 1:40 diluted serum was added to the first well and
four-fold dilutions were carried out to the eighth well. Plates
were incubated for one hour at 37°C, washed three times with
PBS, followed by the addition of anti-human IgG conjugated
to HRP, incubation at room temperature for one hour, and
subsequent addition of HRP substrate. Color development
was continued at room temperature until a low positive con-
trol reached an OD405 of 0.15 in the third or fourth dilution,
at which point the plates were read.
Classification of dengue infections: 1980−1985 school co-
hort study. In the cohort study, a titer of 1:20 for both dengue
antigens, or 1:40 for one, was taken to indicate a past infec-
tion. However, when a serum had titers < 1:40 for dengue,
Sindbis, and Japanese encephalitis viruses, they were not con-
sidered positive since they were thought to be non-specific. A
new dengue infection occurring during the period of this
study was indicated by a four-fold or greater increase in titer
or a conversion from negative to positive against at least two
dengue antigens.
Classification of dengue infections: 1980−1984 clinic study.
Current dengue infections were diagnosed by a four-fold or
greater increase in HI antibody titers between acute and con-
valescent serum samples against any of the four dengue an-
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tigens. An infection was defined as primary when there was
no HI antibody detectable in the acute serum taken four days
or less after onset of illness and the convalescent titer was
 1:640. Secondary dengue infection was diagnosed when the
convalescent titer was  1:1,280 against at least one antigen.34
Secondary infections were also diagnosed when there was
detectable HI antibody in the acute serum sample and a four-
fold increase in the convalescent sample against two dengue
antigens. Samples that did not conform to these criteria were
classified as indeterminate and excluded from statistical
analyses.
Classification of dengue infections: 1997−1998 clinic and
ward studies. Both paired and single serum samples were
tested with a variety of tests. Acute samples (four or fewer
days of fever) were tested by IgM ELISA, RT-PCR, virus
isolation, and HI test or IgG ELISA. Convalescent samples
were only tested by IgM ELISA and HI test. Samples were
scored as positive if 1) they were RT-PCR positive, 2) they
were IgM positive, 3) they had a four-fold increase in HI titer
between acute and convalescent samples, or 4) virus was iso-
lated from the sample. For dengue-positive samples, if the
acute sample ( 4 days after onset) had an HI titer  20 (IgG
> 160), it was defined as a secondary infection. In dengue-
positive cases for which a second serum sample ( 5 days)
was available, an HI titer  1,280 (IgG ELISA titer  40,960)
was considered to represent a secondary infection regardless
of the acute phase titer. Samples that did not conform to these
criteria were classified as indeterminate and excluded from
statistical analyses. Disease severity for dengue cases was de-
fined as follows: 1) Dengue fever with hemorrhage if the
patient had signs of hemorrhage or a platelet count less than
100,000/mm3 and 2) DHF if the patient had signs of hemor-
rhage, evidence of plasma leakage, and a platelet count less
than 100,000/mm3. Dengue cases without any hemorrhagic
symptoms and with platelet counts greater than 100,000/mm3
were classified as DF cases.
Statistical analyses. Data were entered, sorted, and ana-
lyzed by Access® (Microsoft, Redmond, WA). Chi-square,
analysis of variance, Tukey’s honestly significant data test,
Dunnett’s test,35 odds ratios, and confidence intervals were
calculated using SAS and JMP (SAS Institute, Cary, NC),
SPSS (SPSS, Inc., Chicago, IL), or Excel® (Microsoft) soft-
ware. The level of significance for all statistical comparisons
was < 0.05. Age adjustments of clinic surveillance data were
done using three strata of cases: 1−4 years old, 5−8 years old,
and 9−12 years old. The standard population was the summed
1980−1984 population in each strata. Adjustment of propor-
tions and ratios was performed using standard methods as
described by Rothman and Sander.36 Dunnett variances were
weighted by total count for each of the years compared.
RESULTS
Prospective school cohort study. The data from the pro-
spective school cohort study were analyzed to determine the
dengue seroprevalence and six-month infection rate among
5−7-year-old school children. In all, 7,270 children were bled
over the five-year period, averaging 1,454 per year (range 
1,004−1,949) (Table 1). At the time of enrollment, the dengue
seroprevalence in each cohort averaged 50%, indicating fre-
quent exposure of this population to dengue viruses. The six-
month infection rate averaged 15.6% (range  10.8−19.4%),
but in most years the rate was higher than the average (Table
1). The number of primary infections exceeded secondary
infections in every year, and for the five years of the study,
63.4% were classified as primary and 36.6% as secondary
(Table 1). These results establish intense dengue transmission
and frequent exposure to secondary infections among school
children in Colombo from 1980 to 1985.
Clinic and ward studies: demographic characteristics. The
mean ages and sex ratios of people enrolled from 1980 to 1984
and from 1997 to 1998 are shown in Table 2. The 1980−1984
study population had an age range of 0−59 years, and showed
an increasing mean age from 11.17 years in 1980−1981 to
14.44 years in 1983−1984. The difference between these two
means was statistically significant (P < 0.05). The overall ratio
of males to females was 0.90, with more females than males
enrolled every year except 1982−1983. However, the male to
female ratios were not statistically different from year to year.
Because the 1997−1998 data were collected at a pediatric hos-
pital, the mean ages (clinic  5.35 years and ward  6.06
years) were considerably lower than the mean age (12.60) of
people enrolled between 1980 and 1984, which included both
adults and children (Table 2).
Clinic dengue fever surveillance, 1980−1984. An average of
248 (range  137−319) cases per year of fever of unknown
origin (FUO) were studied in five regions of Colombo (Table
3). Overall, 15.96% were confirmed as dengue infections, with
confirmation rates ranging from a low of 12.30% (1981−1982)
to a high of 20.44% (1983−1984). Among the dengue-positive
cases, the number of secondary infections (65.56%) exceeded
the number of primary infections (27.15%), with the number
of secondary infections exceeding the number of primary in-
fections in every complete year (Table 3). There were only 33
documented cases with fever and hemorrhage admitted to
Colombo hospitals during the five years of the study. Of the
33 cases, 11 (33%) were laboratory confirmed as having den-
gue infection, 10 were secondary infections, and one was a
primary infection. None of the cases conformed to the World
Health Organization (WHO) case definition for DHF.
Clinic dengue fever surveillance, 1997−1998. A total of 166
TABLE 1






Total new (%) Primary (%) Secondary (%)
1980–1981 1,230 228 (18.54) 127 (55.70) 101 (44.30)
1981–1982 1,505 252 (16.74) 152 (60.32) 100 (39.68)
1982–1983 1,939 209 (10.78) 142 (67.94) 67 (32.06)
1983–1984 1,592 270 (16.96) 205 (75.93) 65 (24.07)
1984–1985 1,004 164 (16.33) 86 (52.44) 78 (47.56)
Total 7,270 1,123 (15.58) 712 (63.40) 411 (36.60)
* Data are based on seroconversions among 5–7-year-old school children enrolled in a prospective cohort study. Seroconversions are based on hemagglutination inhibition titers.
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FUO cases were studied, of which 41 (24.70%) were dengue
infections (Table 3). The number of primary infections
(56.10%) exceeded the number of secondary infections
(34.15%) in the 1997−1998 clinic study (Table 3).
Ward dengue surveillance, 1997−1998. Eighty-seven sus-
pected DHF cases admitted to the LRH were followed; 51
(58.62%) were confirmed as dengue infections. Among the
hospitalized cases, the number of secondary infections
(62.75%) exceeded the number of primary infections
(19.60%) (Table 3).
Comparison of clinic surveillance data from 1980−1984 and
1997−1998. One plausible explanation for the emergence of
epidemic DHF in 1989 may be an overall increase in dengue
virus transmission, leading to more frequent exposure of
people to dengue infections, and ultimately more frequent
exposure to secondary infections. However, true incidence
data are not available for the post-DHF years. To detect dif-
ference in transmission intensity before and after the emer-
gence of epidemic DHF, we compared the proportion of
people with dengue among FUO clinics and the ratios of
secondary to primary infections in dengue cases among clinic
FUO cases in 1980−1984 and 1997−1998.
The study populations in 1997−1998 were limited to chil-
dren 1-12 years old, while the 1980−1984 study population
included individuals 0–59 years old. Furthermore, the mean
age increased over the course of the 1980−1984 study (Table
2) and the stratified age structures were found to be different
(by chi-square test). Therefore, age is likely to confound com-
parisons within the 1980−1984 study and between the
1980−1984 and 1997−1998 study populations. The data were
age adjusted as detailed in the Materials and Methods section.
The unadjusted proportion of dengue cases among children
with fever ranged from 10.37% in 1981−1982 to a high of
19.72% in 1983−1984 compared with 22.29% in 1997−1998
(Table 4). Following age adjustment, the expected proportion
of dengue cases ranged from 9.76% in 1981−1982 to 18.31%
in 1983−1984; in 1997−1998 it was 18.80% (Table 4). While
the proportions show considerable variability, only
1981−1982 was significantly less than that of 1997−1998 (by
Dunnett’s test). An age-standardized secondary to primary
infection ratio was also calculated for each study year. The
age adjusted ratios of secondary to primary infections for the
1980–1984 study period ranged from 0.5 in 1981 to 2.53 in
1982, while in 1997–1998 the ratio of secondary to primary
infections was 0.75 (Table 4).
Relative distribution of dengue serotypes among patients.
Disease severity may have changed in Sri Lanka because of
changes in the abundance of a particular dengue serotype in
1989. We compared the relative abundance of each serotype
before and after 1989. From the dengue cases identified from
the clinic study conducted from 1980 to 1985, virus was iso-
lated from 56 specimens (Table 5). The relative abundance of
the four serotypes had a distinct pattern, which was domi-
nated by D2 and D3, with D1 and D4 found in considerably
lower abundance. Specifically, D2 was predominant (23 iso-
lates), followed by D3 (20 isolates) and D1 (12 isolates)
(Table 5). D3 was isolated in all five years of the study, D2 in
the first four years, and D1 in three years. Although D4 was
not isolated from any of the cases during the study period, this
serotype was isolated from a U.S. embassy resident in Sri
Lanka in 1981.
Acute serum samples collected in 1989, 1990, 1992, 1994,
TABLE 3














1980–1981 238 38 (15.97) 9 (23.68) 25 (65.79) 4 (10.53)
1981–1982 252 31 (12.30) 10 (32.26) 17 (54.84) 4 (12.90)
1982–1983 319 54 (16.93) 12 (22.22) 39 (72.22) 3 (5.56)
1983–1984 137 28 (20.44) 10 (35.71) 18 (64.29) 0 (0.00)
Total 946 151 (15.96) 41 (27.15) 99 (65.56) 11 (7.23)
1997–1998 clinic 166 41 (24.70) 23 (56.10) 14 (34.15) 4 (9.76)
1997–1998 ward 87 51 (58.62) 10 (19.60) 32 (62.75) 9 (17.64)
* See Materials and Methods for details of how cases were identified as dengue cases and how dengue cases were classified as primary and secondary.
† Indeterminates are dengue-positive cases that could not be classified as primary or secondary.
TABLE 2
Summary of clinic and ward study populations mean ages and sex ratios
Year
(Nov–Oct)













1980–1981 238 11.17A (0–46) 0.71 (99:139) NA* NA NA
1981–1982 252 12.03AB (0–55) 0.92 (121:131) NA NA NA
1982–1983 319 13.31B (1–50) 1.03 (162:157) NA NA NA
1983–1984 137 14.44B (1–59) 0.96 (67:70) NA NA NA
Total (1980–1984) 946 12.60 (0–59) 0.90 (449:497) NA NA NA
1997–1998 166 5.35 (1–12) 0.95 (81:85) 87 6.06 (1–12) 0.67 (35:52)
* NA  not applicable.
† 1980–1984 mean ages that have the same superscript (A or B) are not statistically different (analysis of variance followed by Tukey Honestly Significantly Different test; p < 0.05). 1997–1998
mean ages were not compared to 1980–1984 mean ages because the 1980–1984 study included children and adults whereas the 1997–1998 study only included children 1–12 years old.
‡ The ratios of males to females were not significantly different for any of the clinic study populations.
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1997, and 1998 in Sri Lanka were sent to the Dengue Branch
of CDC in Puerto Rico for virus isolation by mosquito inocu-
lation or C6/36 tissue culture, both followed by IFA. Virus
was isolated from 24 samples. An additional 86 serum
samples collected in 1997 and 1998 were screened by RT-PCR
and C6/36 tissue culture at the MRI in Colombo. As with the
1980–1985 samples, the distribution of serotypes isolated
from 1989 to 1998 (Table 5) had a distinct pattern, with den-
gue 2 predominating (17 isolates), followed by dengue 3 (13
isolates) dengue 1 (10 isolates), and dengue 4 (2 isolates). D2
and D3 were isolated in all years except 1992, D4 was isolated
only in 1992, and D1 was isolated in 1992, 1997, and 1998. The
relative distribution of serotypes isolated from 1980 to 1985
was not significantly different from the relative distribution of
serotypes isolated from 1989–1998 (P > 0.05, by chi-square
test). Rather, the relative distributions are remarkably simi-
lar.
Risk of severe disease with secondary infection. To test
whether secondary infections are associated with an increased
risk of developing severe disease in Sri Lanka following the
emergence of epidemic DHF, we compared the proportion of
primary to secondary infections among dengue patients with
no signs of bleeding (DF) and dengue patients with signs of
hemorrhage (DF plus hemorrhage and DHF cases) (Table 6).
These values gave odds ratios of 0.24 and 4.25 of a severe
disease being associated with a primary or secondary infec-
tion, respectively. These results suggest that once DHF
emerged in Sri Lanka, secondary infections may be a risk
factor for severe disease among people with symptomatic
dengue infections. However, the finding is not statistically
significant (overlapping confidence intervals), suggesting the
need for further study with a larger number of cases.
DISCUSSION
Until now, the epidemiology of dengue infections in Sri
Lanka has not been comprehensively described in the litera-
ture, although the country’s unusual characteristic of a large
number of secondary infections and absence of DHF prior to
1989 has been previously reported.36,37 The results presented
here represent time periods from both before and after the
emergence of epidemic DHF in Colombo, Sri Lanka, and
make it possible to look for changes in the epidemiology of
dengue transmission that correlate with the emergence of
DHF.
Over the period from 1980 to 1985 only 11 cases of hem-
orrhagic disease were detected in Colombo and none of these
met the WHO case definition for DHF. The LRH is the major
children’s hospital in the country, and provides free service
that is used by both the rich and poor. Moreover, the special-
ist pediatricians there provide consultant services to private
hospitals in Colombo. They were informed of the DF/DHF
surveillance program, were aware of the dangers of DHF, and
had been instructed in its clinical diagnosis and management.
The outpatient staff at the LRH had also been instructed to
admit all cases of fever with bleeding to the ward of the
professor of pediatrics, who was participating in this study.
Given the extent of awareness about dengue between 1980
and 1985, it is unlikely that epidemics of DHF occurred un-
noticed by health authorities and on a scale similar to that
that occurred after 1989.
The low number of DHF cases was not due to lack of
exposure to dengue viruses. The prospective school cohort
survey conducted from 1980 to 1985 demonstrated a sero-
prevalence of 50% and a six-month seroconversion rate of
15% among 5−7-year-old school children. The FUO clinic
surveillance program also confirmed that dengue transmis-
sion and secondary infections were common in Colombo over
this period, with secondary infections accounting for 59% of
all dengue cases. Moreover, an outbreak with DEN-2 as the
predominant virus serotype occurred in the fall of 1983. De-
spite a high rate of secondary infections, there were no DHF
cases detected.38
The lack of DHF was not due to hypoendemicity. Multiple
dengue virus serotypes (DEN-1, DEN-2, and DEN-3) circu-
lated simultaneously in Colombo throughout most of the
study period. Although dengue 4 was not isolated during
1980–1985 surveillance, there is evidence it was also circulat-
ing in Colombo from plaque reduction neutralization test as-
says on serum samples.38 If antibody dependent enhancement
were the sole mechanism responsible for severe dengue dis-
ease, then one would have expected considerably more DHF
in Colombo, Sri Lanka, from 1980 to 1985 given the intensity
of transmission of multiple virus serotypes in Colombo over
the period 1980–1985.
It is plausible that the DHF epidemics in 1989 started be-
cause the intensity of transmission increased above the levels
observed in 1980–1984. Using dengue cases among children
with FUO as a surrogate for dengue virus activity in Co-
lombo, we did not find evidence for a large increase in virus
activity following the emergence of epidemic DHF. Over the
period 1980–1984, 10.37–19.72% (Table 4) of FUO cases (un-
adjusted) were due to dengue, whereas in 1997–1998, the pro-
portion was 22.29% (Table 4). Following age-adjustment,
TABLE 4

















1980–1981 157 23 14.65 13.38 7 (30.43) 16 (69.57) 2.21
1981–1982† 164 17 10.37 9.76 12 (70.58) 5 (29.42) 0.50
1982–1983 191 29 15.18 13.61 8 (27.59) 21 (72.41) 2.53
1983–1984 71 14 19.72 18.31 7 (50.00) 7 (50.00) 1.00
Total (1980–1984) 583 83 19.24 NA 34 (30.96) 49 (59.04) 1.44
1997–1998 166 37 22.29 18.80 23 (62.16) 14 (37.84) 0.75
* Cases are for patients 1–12 years old. Age-adjusted proportions and ratios were calculated as described in the Materials and Methods. NA  not applicable.
† Different from the 1997–1998 proportion by Dunnett test (P < 0.05).
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only the 1981–1982 proportion was significantly less than that
of the 1997–1998 proportion of dengue cases. The 1997–1998
data were collected over relatively short periods (five weeks
in 1997 and five weeks in 1998) and may not reflect dengue
transmission over the entire year. In fact, the two five-week
periods (July–August 1997 and December–January 1998) rep-
resent periods of high transmission because they coincide
with the southwest and northeast monsoons, respectively.
Therefore, the short sampling periods in 1997–1998 are more
likely to overestimate than underestimate dengue activity in
and around Colombo.
As a more stable estimate of intensity of dengue transmis-
sion, we also calculated an age-adjusted ratio of primary to
secondary infections among children with dengue before and
after the emergence of epidemic DHF (Table 4). The greater
the ratio’s value, the more intense dengue transmission is
likely to be, yielding more secondary infections in a young
(1–12-years old) population. The ratios of secondary to pri-
mary infections show considerable variation from one year to
the next for the 1980–1984 study data, but only one year,
1981–1982, had a ratio less than 1. A low value, 0.75 for 1997–
1998, suggests a lower intensity of transmission because fewer
children were presenting with secondary infections. In fact,
the data presented here suggest that the intensity of transmis-
sion may have decreased since DHF emergence, with only
three of the four pre-DHF years having secondary to primary
ratios greater than or equal to 1. However, the statistical
power to resolve such a change is lacking in this study. How-
ever, taken together, our results do not point to an overall
increase in dengue transmission or the proportion of second-
ary infections following the emergence of epidemic DHF in
Sri Lanka.
Finally, another possible explanation for the emergence of
epidemic DHF in Sri Lanka could be an increase in the preva-
lence of a particular virus serotype. Dengue virus serotypes
throughout the world have been correlated with epidemic
DHF elsewhere, particularly in Thailand39,40 and Latin
America with DEN-2,1,20,22,41 and Indonesia,34 the Ameri-
cas,1,21 and the Pacific islands24 with DEN-3. While Sri Lanka
has had endemic circulation of all four virus serotypes, they
do not occur in equal abundance. Therefore, shifts in the
relative abundance of the serotypes could be correlated with
changes in DHF. Clearly, DEN-1, DEN-2, and DEN-3 circu-
lated throughout the period 1980–1985, and there is evidence
that dengue 4 circulated as well. When compared with the
distribution of isolates collected from 1989 to 1998, the two
distributions are remarkably similar (Table 5). Far from sug-
gesting that there has been a shift in the relative abundance of
the four serotypes in Sri Lanka, these data suggest that the
serotype distribution has remained stable through the emer-
gence of DHF in Sri Lanka. The stability of the relative dis-
tribution of the virus serotypes further implies that dengue
virus ecology in Sri Lanka, the collective interactions between
the virus, its vector, human host, and the environment, may
itself be relatively stable because the distribution of the virus
serotypes has been maintained.
Previous studies have found a greater risk of hospitalization
and severe disease with secondary infections compared with
primary infections.13 We tested whether secondary infections
were a risk factor for severe disease during the 1997–1998
ward studies. We designated severe and mild disease based on
the presence or absence of signs of hemorrhage in confirmed
dengue cases. We did not use the WHO criteria alone for
identifying severe disease cases because for many of the cases
the hematocrit and platelet counts were not available. When
cases were separated based on dengue infection with or with-
out hemorrhagic manifestations, secondary infections were
found to increase the odds of severe disease by 4.25 fold
among people with symptomatic dengue infections. However,
a study with a larger sample size is needed to confirm this
association. Although secondary infections most likely con-
tribute to DHF, the near absence of severe disease from 1980
to 1984 clearly demonstrates that some element other than
immune enhancement is necessary for DHF to be present in
a population.
The emergence of DHF in Sri Lanka was dramatic and
persistent, suggesting that an equally dramatic and persistent
change in the disease cycle occurred. The findings presented
here indicate that no such change occurred in either virus
serotype distribution, intensity of transmission, or proportion
of secondary infections occurring in Colombo. Additionally,
these findings lend credibility to the hypothesis first suggested
by Rosen, Gubler, and others16−18 that virus strain is an im-
portant risk factor for DHF, and advanced by Lanciotti and
others that small genotypic changes in dengue viruses are
responsible for the DHF emergence in Sri Lanka.42 Such a
change could be both dramatic and persistent but would be
undetected by the epidemiologic approach used here. We are
currently undertaking molecular genetic studies of dengue
viruses isolated from DF and DHF patients in Sri Lanka over
TABLE 6
Risk of severe disease with secondary infection*
Status DFhem + DHF DF Total
Odds ratio
(95% CI)
Secondary 17 29 46 4.25 (0.75–23.9)
Primary 4 29 33 0.24 (0.04–1.35)
Total 21 58 79
* The hemorrhagic (DFhem plus dengue hemorrhagic fever [DHF]) and dengue fever
(DF) cases are from the 1997 and 1998 ward and clinic studies. The odds ratio compares the
risk of developing severe disease among symptomatic dengue cases with primary and sec-
ondary infections. CI  confidence interval.
TABLE 5











1980–1985 12 (21.43) 23 (41.07) 20 (35.71) 1 (1.79) 56
1989–1998 10 (23.81) 17 (40.48) 13 (30.95) 2 (4.76) 42
Total 22 (22.45) 40 (40.82) 33 (33.67) 3 (3.06) 98
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the study period 1980–1998. The results of those studies,
which we hope to complete shortly, may provide more data
on the genotype hypothesis.
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